BioCentury
ARTICLE | Company News

UCB, ConfometRx in GPCR discovery deal

February 22, 2013 2:05 AM UTC

UCB Group (Euronext:UCB) and structural biology company ConfometRx (Santa Clara, Calif.) partnered to research GPCR modulation to discover new therapies for neuroscience indications. The two-year deal includes an undisclosed upfront payment, research funding and milestones, but the partners did not disclose details. ...